Mental health disorders are a serious and growing public health issue. According to the World Health Organization, more than 264 million people worldwide suffer from depression, and approximately one million people die by suicide every year. Despite advances in psychopharmacology, many of these individuals are not able to find adequate relief from existing treatments. However, a new treatment option, ketamine, is offering hope to those suffering from mental health disorders. Ketamine, a powerful anesthetic used in surgery, is now being used off-label as a treatment for depression, anxiety, post-traumatic stress disorder (PTSD), and other mental health disorders. It has been found to be effective in reducing symptoms within hours or days, and its effects can last for weeks or months. This is in stark contrast to traditional antidepressants, which can take weeks or months to take effect.
Ketamine works by blocking the N-methyl-D-aspartate (NMDA) receptor, which is involved in the regulation of mood. It is thought to increase the release of glutamate, a neurotransmitter involved in the regulation of mood, and to increase the activity of the neurotransmitter gamma-aminobutyric acid (GABA), which is involved in the regulation of anxiety. Ketamine is administered intravenously, either as a single dose or as a series of doses. The effects of a single dose can last up to 72 hours, while the effects of a series of doses can last up to several weeks.
Ketamine has been found to be effective in treating a variety of mental health disorders, including depression, anxiety, PTSD, and obsessive-compulsive disorder (OCD). It has been found to be particularly effective in treating treatment-resistant depression, which is depression that does not respond to traditional antidepressants. Ketamine has also been found to be effective in reducing suicidal ideation. In a study of patients with treatment-resistant depression, ketamine was found to reduce suicidal ideation within 24 hours. This is particularly important, as suicide is the leading cause of death among people with mental health disorders. Ketamine has also been found to be effective in reducing symptoms of PTSD. In a study of veterans with PTSD, ketamine was found to reduce symptoms of PTSD within 24 hours. This is particularly important, as PTSD is a debilitating disorder that can have long-term effects.
Ketamine is generally well-tolerated, but it can have some side effects. Common side effects include nausea, dizziness, headache, and confusion. Less common side effects include increased heart rate, increased blood pressure, and hallucinations. It is important to note that ketamine can be abused. Ketamine is a Schedule III controlled substance, meaning that it has a high potential for abuse and can be legally prescribed by a doctor.
Ketamine is a revolutionary treatment for mental health disorders that has been found to be effective in reducing symptoms within hours or days. It has been found to be particularly effective in treating treatment-resistant depression, suicidal ideation, and PTSD.
1.
Are patients with advanced cancer receiving treatment aligned with their goals?
2.
For MDS-Related Anemia, Telomerase Inhibitor Approved.
3.
Month-Long Wait Times Caused by US Physician Shortage.
4.
Reasons Behind Refusing Stem Cell Transplantation in Certain Myeloma Patients.
5.
Cancer patients rarely use ancestry testing.
1.
Myeloproliferative Disorders: Causes, Symptoms and Treatment Options
2.
Epigenetics and Resistance: Mechanisms in Histone Methylation-Targeted Therapies
3.
Multidisciplinary Insights into Diagnosis, Management, and Outcomes in Oncology
4.
The Benefits and Side Effects of Bortezomib in the Fight Against Cancer
5.
Respiratory Ramifications of Systemic Disease: A Comprehensive Review
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Updates on Standard V/S High Risk Myeloma Treatment
2.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
3.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
4.
Current Scenario of Cancer- Q&A Session to Close the Gap
5.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation